BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company specializing in novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today that its management will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026, in New York City.
The presentation, featuring Hernan Levett, Chief Financial Officer of BioVersys, is set for September 16, 2026, from 12:30 PM to 1:00 PM ET at the Kennedy II room on the 4th floor of the Lotte New York Palace. Additionally, an on-demand presentation by Dr. Marc Gitzinger, Chief Executive Officer, will be available live on September 11, 2026, at 7:00 AM ET, with a replay accessible for 90 days via the H.C. Wainwright platform or the BioVersys website in the investor section.
This announcement is significant as it provides BioVersys an opportunity to showcase its pipeline and strategic vision to a global investment audience. The company focuses on addressing one of the most pressing public health threats: antimicrobial resistance (AMR). By developing treatments for MDR bacterial infections, BioVersys aims to mitigate the growing challenge of infections that are increasingly resistant to existing antibiotics, which poses a major risk to global health, potentially leading to longer hospital stays, higher medical costs, and increased mortality.
BioVersys leverages two internal technology platforms: TRIC and Ansamycin Chemistry. These platforms are designed to overcome resistance mechanisms, block virulence production, and directly affect the pathogenesis of harmful bacteria. The company's lead programs target nosocomial infections caused by Acinetobacter baumannii (BV100, Phase 3) and tuberculosis (alpibectir, Phase 2, in collaboration with GlaxoSmithKline (GSK) and a consortium from the University of Lille, France). These programs address high unmet medical needs for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders.
The conference participation is particularly important for BioVersys as it seeks to attract investment to advance its clinical trials and potentially bring these much-needed therapies to market. The world health community has been calling for increased research and development in antibacterials, and BioVersys' progress represents a step forward in tackling diseases that have become resistant to current treatment options.
Attendees of the conference will have the opportunity to engage with BioVersys' leadership, including the CEO and CFO, who will be available for one-on-one meetings. This engagement could facilitate partnerships and investment that support the company's mission.
BioVersys, headquartered in Basel, Switzerland, continues to position itself as a key player in the antimicrobial field. The company's participation in the H.C. Wainwright conference underscores its commitment to advancing its pipeline and its potential impact on public health.
